Currently Viewing:
Newsroom
Currently Reading
What We're Reading: States to Recalibrate Hospital Payments; Mumps Outbreak; Tuberculosis Eradication Plan
March 21, 2019 – AJMC Staff
Novo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable
March 21, 2019 – Mary Caffrey and Samantha DiGrande
Continuing Systemic Treatment in Cutaneous T-cell Lymphoma Associated With Lower Healthcare Costs
March 20, 2019 – Mary Caffrey
Genomic Testing Can Reduce Costs by $6600 for Certain Patients With Breast Cancer
March 20, 2019 – Laura Joszt
Adherence to COPD Treatment Lower With 3 Inhalers Compared With 2
March 20, 2019 – Jaime Rosenberg
CDC Says New HIV Transmissions Stem From Lack of Treatment, Unawareness of Infection
March 20, 2019 – Wallace Stephens
What We're Reading: Postpartum Depression Drug Approval; Marijuana and Psychosis; Mississippi Abortion Bill
March 20, 2019 – AJMC Staff
AHIP, Employer Groups Seek Congressional Action on Surprise Medical Bills
March 19, 2019 – Allison Inserro
The Current Landscape of CGRP Inhibitor Coverage
March 19, 2019 – Samantha DiGrande

Pentraxin-3 Plasma Levels May Help Guide Clinical Decision-Making in Primary Myelofibrosis

Kelly Davio
Pentraxin-3 is known to promote the transition of monocytes to fibrocytes, though little is known about its role in myelofibrosis.
Primary myelofibrosis (PMF), a rare myeloproliferative neoplasm, involves enlarged spleen, hematopoiesis occurring in organs outside of the bone marrow, and progressive bone marrow (BM) fibrosis. The level of BM fibrosis is known to correlate with poor survival.

Writing in a letter to The British Journal of Haematology, a research team explained that, in seeking to identify the mechanism of BM fibrosis, they identified large numbers of fibrocytes in the BM, as well as increased levels of the pentraxin C-reactive protein (CRP) in the plasma, of patients with PMF. Another pentraxin, pentraxin-3 (PTX3), is known to promote the transition of monocytes to fibrocytes, though little is known about PTX3’s role in PMF.

The team examined PTX3 plasma levels from 140 patients with PMD and compared them with 30 samples from healthy volunteers, and found that PTX3’s plasma levels were significantly higher in patients with PMF, as were CRP plasma levels. They also found that high CRP levels were associated with unfavorable overall survival (OS).

Using a multivariate Cox proportional hazard regression model, the researchers found that OS was independently predicted by both PTX3 (HR, 1.77, P = .03) and CRP (HR, 1.95, P = .019). Furthermore, high PTX3 and high CRP correlated with unfavorable prognostic indicators identified in the Dynamic International Prognostic Scoring System’s risk stratification.

Furthermore, PTX3 levels were also correlated with parameters of tumor burden, including total leucocyte count and spleen size, and with the severity of patients’ constitutional symptoms and performance status.

“Our data suggest that PTX3 plasma levels constitute an independent indicator of disease burden, clonal expansion and overall survival in patients with PMF,” concluded the authors. “Therefore, monitoring of PTX3 plasma levels might be a useful tool in clinical decision making.”

Reference

Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z. Pentraxin-3 plasma levels correlate with tumor burden and overall survival in patients with primary myelofibrosis. [Published online August 3, 2018.] Br J Haematol. doi: 10.1111/bjh.15528.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!